Results 191 to 200 of about 45,859 (253)

Learning Strategies from Nature's Blueprint to Cyclic Carbonate Synthesis

ChemSusChem, Volume 18, Issue 6, March 15, 2025.
The development of sustainable synthetic methods for cyclic carbonates draws inspiration from nature, focusing on eco‐friendly processes and renewable resources like CO2 and biomass. This review explore various CO2 activation mechanisms, green chemistry principles, and green catalysts.
Erika Saccullo, Vincenzo Patamia, Chiara Zagni, Antonio Rescifina, Giuseppe Floresta   +4 more
wiley   +1 more source

A biology-based quality-diversity algorithm for drug repurposing in Alzheimer's disease using automated machine learning. [PDF]

BioData Min
Shao S, Ribeiro PH, Orlenko A, Cardone KM, Ramirez CM, Shen L, Ritchie MD, Moore JH.   +7 more
europepmc   +1 more source

Low‐Dimensional Materials and Van Der Waals Heterostructures for Energy Application: A Comprehensive Review

ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
Low‐dimensional materials (0D, 1D, and 2D) exhibit unique electronic and physicochemical properties, enabling advanced nanoelectronic and optoelectronic devices. Mixed‐dimensional heterostructures combine these materials to enhance functionality.
Qaisar Alam, Sajjad Ali, Pir Muhammad Ismail, ABM Sharif Hossain   +3 more
wiley   +1 more source

FusionTarget: Computational framework for drug repurposing against modeled fusion protein structures from genomic breakpoints. [PDF]

iScience
Kumar H, Tsang SV, Lee MS, Huang YH, Choi J, Lotlikar SR, Song JY, Toh A, Choi YL, Brannan KW, Kim P.   +10 more
europepmc   +1 more source

Lignocellulosic Triboelectric Materials for Energy Harvesting and Emerging Applications: A Review on Lignin‐Molecular Engineering toward Improved Performance

ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
Contrasting sustainable biomass with depleting petroleum resources, this review charts the evolutionary timeline of lignin‐based TENGs. We systematically evaluate their fundamental mechanisms, enhancement strategies, and applications in green self‐powered electronics.
Yuxin Yang, Boyu Du, Yuwen Wang, Tian Tang, Yuxuan Xie, Jiajun Zhang, Yajun Zhang, Jingyu Xu, Xing Wang, Chuanyin Xiong   +9 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Drug Repurposing for Kala-Azar. [PDF]

Pharmaceutics
Arsić B, Ilić BS, Maier A, Hartung M, Janjić J, Milićević J, Baumbach J.   +6 more
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Benchmarking heterogeneous network-based methods for drug repurposing. [PDF]

NPJ Syst Biol Appl
Nguyen TT, Pawitan Y, Calza S, Vu TN.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source